Keros Therapeutics Inc Stock News

LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provid...

LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' C...

NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ:KROS) on behalf of Keros stockholders. Our investigation concerns whether Keros has violated the federal securities laws and/or engaged in other unlawful business practi...

NEW YORK--(BUSINESS WIRE)---- $KROS #CLASSACTIONLAWSUIT--The law firm of Kirby McInerney LLP is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ:KROS). The investigation concerns whether Keros and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more ab...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of its experimental hypertension treatment due to safety concerns during a mid-stage trial.

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announ...

Keros Therapeutics' stock plummeted due to safety concerns in its Phase 2 TROPOS trial, but the risk-reward profile remains favorable for a rebound. The stock's enterprise value dropped drastically, now trading at essentially cash value, bolstered by a $200 million upfront payment from Takeda. Despite a high burn rate, Keros' cash runway extends into Q4 2028, with potential milestone payments f...

Keros Therapeutics stock plummeted Thursday after the company stopped giving higher doses in a lung disease study due to side effects. The post Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study appeared first on Investor's Business Daily.